WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term:

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ Hit List ◎ Hit Count ○ Side by Side ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Monday, March 11, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L17	L16 same l2	27	L17
L16	cosmetic composition	12424	L16
L15	L13 and l2	141	L15
L14	L13 same l2	1	L14
L13	mascara	2587	L13
L12	L11 not (l8 or l3)	39	L12
L11	l2 with l6	39	L11
L10	l2 same l6	110	L10
L9	l2 and l6	388	L9
L8	L7 not l3	10	L8
L7	l5 and l6	10	L7
L6	minoxidil or rogaine	1596	L6
L5	l4 or prostaglandin f	1681	L5
L4	pgf	1418	L4
L3	l1 same l2	5	L3
L2	prostaglandin or pg or pg$3	154326	L2
L1	oximyl or hydroxylamino	1122	L1

END OF SEARCH HISTORY

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1619lxw
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 6	Oct 22	Over 1 million reactions added to CASREACT
NEWS 7	Oct 22	DGENE GETSIM has been improved
NEWS 8	Oct 29	AAASD no longer available
NEWS 9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS 10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS 11	Nov 29	COPPERLIT now available on STN
NEWS 12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS 13	Nov 30	Files VETU and VETB to have open access
NEWS 14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 15	Dec 10	DGENE BLAST Homology Search
NEWS 16	Dec 17	WELDASEARCH now available on STN
NEWS 17	Dec 17	STANDARDS now available on STN
NEWS 18	Dec 17	New fields for DPCI
NEWS 19	Dec 19	CAS Roles modified
NEWS 20	Dec 19	1907-1946 data and page images added to CA and CAplus
NEWS 21	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 22	Jan 25	Searching with the P indicator for Preparations
NEWS 23	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 24	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 25	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 26	Mar 08	Gene Names now available in BIOSIS

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:40:59 ON 12 MAR 2002

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 09:41:04 ON 12 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 10 MAR 2002 HIGHEST RN 400003-05-6
DICTIONARY FILE UPDATES: 10 MAR 2002 HIGHEST RN 400003-05-6

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the H/Z/CA/CAplus files between 12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches during this period, either directly appended to a CAS Registry Number or by qualifying an L-number with /P, may have yielded incomplete results. As of 1/23/02, the situation has been resolved. Also, note that searches conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator between 12/27/01 and 1/23/02, are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to help@cas.org for further assistance or to receive a credit for any duplicate searches.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\STNEXP4\QUERIES\5.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> s l2

```
SAMPLE SEARCH INITIATED 09:41:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1331 TO ITERATE

 75.1% PROCESSED    1000 ITERATIONS                                 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        24432 TO    28808
PROJECTED ANSWERS:              32 TO      446

L3            9 SEA SSS SAM L1

=> s l2 full
FULL SEARCH INITIATED 09:41:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  27310 TO ITERATE

100.0% PROCESSED   27310 ITERATIONS                             183 ANSWERS
SEARCH TIME: 00.00.02

L4          183 SEA SSS FUL L1

=> fil caplus uspatfull medline biosis embase
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             140.22     140.37

FILE 'CAPLUS' ENTERED AT 09:41:46 ON 12 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:41:46 ON 12 MAR 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:41:46 ON 12 MAR 2002

FILE 'BIOSIS' ENTERED AT 09:41:46 ON 12 MAR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:41:46 ON 12 MAR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

=> s l4
L5           55 L4

=> s l2
SUBSTANCE QUERIES NOT VALID IN THIS FILE
SUBSTANCE QUERIES NOT VALID IN THIS FILE
SUBSTANCE QUERIES NOT VALID IN THIS FILE
SUBSTANCE QUERIES NOT VALID IN THIS FILE
SUBSTANCE QUERIES NOT VALID IN THIS FILE
The logic expression entered contains L#s or saved query names which
correspond to structures built by the STRUCTURE command or to screen
sets.  These must be searched in a substance file such as the REGISTRY
file.  In some files you may use a Registry Number answer set from a
structure search as a search term or profile in some bibliographic
file containing Registry Numbers, e.g.  the CA file.  For an
explanation, enter "HELP CROSSOVER" at an arrow prompt (=>).
```

```
=> dup rem l5
PROCESSING COMPLETED FOR L5
L6           49 DUP REM L5 (6 DUPLICATES REMOVED)

=> s prostaglandin
L7       289547 PROSTAGLANDIN

=> s l6 and l7
L8           44 L6 AND L7

=> s hair
L9       169447 HAIR

=> s cosmetic or pharmaceutic or pharmaceutical
L10      494459 COSMETIC OR PHARMACEUTIC OR PHARMACEUTICAL

=> s l8 andl 9
MISSING OPERATOR L8 ANDL
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l8 and l9
L11          3 L8 AND L9

=> s l8 and l10
L12          8 L8 AND L10

=> d ibib abs hitstr l11

L11  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         2001:747564  CAPLUS
DOCUMENT NUMBER:          135:293970
TITLE:                    Cosmetic and pharmaceutical compositions and methods
                          using 2-decarboxy-2-phosphinico prostaglandin
                          derivatives
INVENTOR(S):              Delong, Mitchell Anthony; Mciver, John Mcmillan;
                          Youngquist, Robert Scott
PATENT ASSIGNEE(S):       The Procter + Gamble Company, USA
SOURCE:                   PCT Int. Appl., 54 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2001074314      A2   20011011       WO 2001-US10369  20010330
         W:  AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI,
             FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
             MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM,
             TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2002013294      A1   20020131       US 2001-774558   20010131
```

PRIORITY APPLN. INFO.: US 2000-193845 P 20000331
OTHER SOURCE(S): MARPAT 135:293970

AB Compns. contg. 2-decarboxy-2-phosphinico **prostaglandin** derivs. is described for treating **hair** loss in mammals. The compns. can be applied topically to the skin to arrest **hair** loss, reverse **hair** loss, and promote **hair** growth. Compns. contg. 2-decarboxy-2-phosphinico **prostaglandin** derivs. can also be used to lower intraocular pressure and treat bone disorders. A compn. comprises a **prostaglandin** analog, an activity enhancer, such as a **hair** growth stimulant and a penetration enhancer, and a sufficient amt. of a component selected from the group consisting of emollients, propellants, solvents, humectants, thickeners, powders, fragrances, water, alcs., aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, polypropylene glycol-2 myristyl propionate, di-Me isosorbide, and combinations thereof. For example, a compn. for topical administration was prepd. comprising (by wt.) a **prostaglandin** (IC50 = 114 nM) 1.14%, ethanol 59.32%, propylene glycol 19.77%, and di-Me isosorbide 19.77%. Also, a shampoo was made contg. ammonium lauryl sulfate 11.5%, ammonium laureth sulfate 4%, cocamide MEA 2%, ethylene glycol distearate 2%, cetyl alc. 2%, stearyl alc. 1.2%, glycerin 1%, sodium chloride 0.1%, sucrose polyesters of cottonate fatty acid 3%, sucrose polyesters of behenate fatty acid 2%, lauryl di-Me amine oxide 1.5%, DMDM hydantoin 0.15%, **prostaglandin** (IC = 150 nM) 0.15%, phenoxyethanol 0.5%, fragrance 0.5%, and water up to 100%. A tablet formulation was also prepd. contg. a **prostaglandin** 5 mg, microcryst. cellulose 100 mg, sodium starch glycolate 30 mg, and magnesium stearate 3 mg per tablet. When administered orally once daily, the above compn. substantially increases bone vol. in a patient suffering from osteoporosis.

IT **365241-18-5P 365241-19-6P 365241-20-9P**
365241-21-0P 365241-22-1P 365241-23-2P
365241-24-3P 365241-25-4P 365241-26-5P
365241-27-6P
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cosmetic and pharmaceutical compns. contg. 2-decarboxy-2-phosphinico **prostaglandin** derivs.)

RN 365241-18-5 CAPLUS

CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-[(3-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-19-6 CAPLUS
CN Phosphinic acid, ethyl[6-[(1R,5S)-2-[(3R)-4-[(2-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-20-9 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-(3-fluorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-21-0 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxyoctyl]cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-22-1 CAPLUS

CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxynonyl]cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-23-2 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-24-3 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-[(2,4-difluorophenyl)amino]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-25-4 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-2-[(3S)-3-hydroxyoctyl]-3-

(methoxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-26-5 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-(benzo[b]thien-3-ylthio)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-27-6 CAPLUS
CN Phosphinic acid, butyl[6-[(1R,5S)-2-[(3R)-5-(2-fluorophenyl)-3-hydroxy-4-pentynyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=> d 2 ibib abs hitstr l11

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:747558 CAPLUS
DOCUMENT NUMBER: 135:293969
TITLE: Compositions and methods for treating **hair** loss using oximyl- and hydroxylamino-prostaglandins
INVENTOR(S): Delong, Mitchell Anthony; Mciver, John Mcmillan; Youngquist, Robert Scott
PATENT ASSIGNEE(S): The Procter + Gamble Company, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074307	A2	20011011	WO 2001-US10547	20010330

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-193844 P 20000331
OTHER SOURCE(S): MARPAT 135:293969

AB A compn. for treating **hair** loss in mammals comprises a **prostaglandin** analog, an activity enhancer in an amt. of 1-20%, and a sufficient amt. of a component selected from the group consisting of emollients, propellants, solvents, humectants, thickeners, powders, fragrances, water, alcs., aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, polypropylene glycol-2 myristyl propionate, di-Me isosorbide, and combinations thereof. The compns. can be applied topically to the skin to arrest **hair** loss, reverse **hair** loss, and promote **hair** growth. A compn. for topical administration was prepd. comprising (by wt.) a **prostaglandin** (IC50 = 150 nM) 0.1%, ethanol 59.9%, propylene glycol 20.0%, and di-Me isosorbide 20.0%. Also, a shampoo was made contg. ammonium lauryl sulfate 11.5%, ammonium laureth sulfate 4%, cocamide MEA 2%, ethylene glycol distearate 2%, cetyl alc. 2%, stearyl alc. 1.2%, glycerin 1%, sodium chloride 0.1%, sucrose polyesters of cottonate fatty acid 3%, sucrose polyesters of behenate fatty acid 2%, lauryl di-Me amine oxide 1.5%, DMDM hydantoin 0.15%, **prostaglandin** (IC50 = 150 nM) 0.15%, phenoxyethanol 0.5%, fragrance 0.5%, and water up to 100%. A topical pharmaceutical compn. for lowering intraocular pressure was also prepd. contg. **prostaglandin** 0.004%, dextran 70 0.1%, hydroxypropyl Me cellulose 0.3%, sodium chloride 0.77%, potassium chloride 0.12%, disodium EDTA 0.05%, benzalkonium 0.01%, HCl and/or NaOH to pH 7.2-7.5, and water to 100%. The compn. was administered ocularly to a subject once per day for 6 to 12 wk to promote eyelash growth.

IT **245127-04-2P 365400-66-4P 365400-67-5P**

365400-68-6P 365400-69-7P 365400-70-0P
365400-71-1P 365400-72-2P 365400-73-3P
365400-74-4P 365400-75-5P 365400-76-6P
365400-77-7P 365400-78-8P 365400-79-9P
365400-80-2P 365400-81-3P 365400-82-4P
365400-83-5P 365400-84-6P 365400-85-7P
365400-86-8P 365400-87-9P 365400-88-0P
365400-89-1P 365400-90-4P 365400-91-5P
365400-92-6P 365401-05-4P 365401-06-5P
365401-07-6P 365401-09-8P 365401-11-2P
365401-12-3P 365401-13-4P 365401-14-5P
365401-15-6P 365401-16-7P 365401-17-8P
365401-18-9P 365401-19-0P 365401-20-3P
365401-21-4P 365401-22-5P 365401-23-6P
365401-24-7P 365401-25-8P 365401-26-9P
365401-27-0P 365401-28-1P 365401-29-2P
365401-30-5P 365401-31-6P 365401-32-7P
365401-33-8P 365401-34-9P 365401-35-0P
365401-36-1P 365401-37-2P 365401-38-3P
365401-39-4P 365401-40-7P 365401-41-8P
365401-42-9P 365401-43-0P 365401-44-1P
365401-45-2P 365401-52-1P 365401-53-2P
365401-54-3P 365401-56-5P 365401-58-7P
365401-59-8P 365401-60-1P 365401-62-3P
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(topical compns. contg. oximyl- and hydroxylamino-prostaglandins for treating **hair** loss)

RN 245127-04-2 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[3-hydroxy-4-(phenylthio)butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-66-4 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[4-[(2,4-difluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)-, methyl ester, (1R,2R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-67-5 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-4-(2,4-difluorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-68-6 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-4-[(2,4-difluorophenyl)amino]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)-, methyl ester, (1R,2R,5S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-69-7 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-4-[(4-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)-, ethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-70-0 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-4-(4-fluorophenoxy)-3-hydroxybutyl]-5-
hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-71-1 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-5-
hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-72-2 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-4-(3-chlorophenoxy)-3-hydroxypentyl]-5-
hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-73-3 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
[(2-methoxyphenyl)thio]butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-74-4 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
[(3-methoxyphenyl)thio]butyl]-, 1-methylethyl ester, (1R,2R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-75-5 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
[(2-thienylmethyl)thio]butyl]-, methyl ester, (1R,2R,5S)- (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-76-6 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
[3-(trifluoromethyl)phenoxy]butyl]-, methyl ester, (1R,2R,5S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-77-7 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
(2-methylphenoxy)butyl]-, 2,3-dihydroxypropyl ester, (1R,2R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-78-8 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
[(3-methylphenyl)thio]butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 365400-79-9 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-
(phenylthio)butyl]-, methyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-80-2 CAPLUS
CN 5-Heptenoic acid,
7-[(1R,2R,5S)-2-[(1E,3R)-4-(2-fluorophenoxy)-3-hydroxy-1-
butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-81-3 CAPLUS
CN 5-Heptenoic acid,
7-[(1R,2R,5S)-2-[(1E,3R)-4-[(2,4-difluorophenyl)thio]-3-
hydroxy-1-butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester,
(5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



RN 365400-82-4 CAPLUS
CN 5-Heptenoic acid,
7-[(1R,2R,5S)-2-[(1E,3R)-4-[(3,5-difluorophenyl)amino]-3-
hydroxy-1-butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, (5Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-83-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E,3R)-4-[(2-fluorophenyl)thio]-3-
hydroxy-1-butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester,
(5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-84-6 CAPLUS
CN 5-Heptenoic acid,
7-[(1R,2R,5S)-2-[(1E,3R)-4-(4-fluorophenoxy)-3-hydroxy-1-
butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, ethyl ester, (5Z)-
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-85-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E,3R)-4-[(4-fluorophenyl)thio]-3-hydroxy-1-butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-86-8 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-(2-methoxyphenoxy)butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365400-87-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-phenoxybutyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-88-0 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E,3R)-3-hydroxy-4-(2-thienylmethoxy)-1-butenyl]cyclopentyl]-, methyl ester, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-89-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-90-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E,3R)-3-hydroxy-4-(2-methylphenoxy)-1-butenyl]cyclopentyl]-, methyl ester, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-91-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E,3R)-3-hydroxy-4-(3-methylphenoxy)-1-butenyl]cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365400-92-6 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-phenoxypentyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-05-4 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E)-4-(2-fluorophenoxy)-3-hydroxy-3-methyl-1-butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-06-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E)-3-hydroxy-3-(phenoxymethyl)-1-pentenyl]cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-07-6 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[3-hydroxy-3-(phenoxymethyl)pentyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-09-8 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E)-4-(2-fluorophenoxy)-3-methyl-3-

(methylamino)-1-butenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-11-2 CAPLUS
CN Cyclopentaneheptanamide,
N,5-dihydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-12-3 CAPLUS
CN 5-Heptenamide,
7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E)-3-hydroxy-4-phenoxy-1-butenyl]cyclopentyl]-N-(methylsulfonyl)-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-13-4 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3S)-6-(2-fluorophenyl)-3-hydroxyhexyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-14-5 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-5-(2,4-difluorophenyl)-3-hydroxypentyl]-5-hydroxy-3-(hydroxyimino)-, methyl ester, (1R,2R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-15-6 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-5-(3,5-difluorophenyl)-3-hydroxypentyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-16-7 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-5-(3-fluorophenyl)-3-hydroxypentyl]-5-

hydroxy-3-(hydroxyimino)-, methyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-17-8 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-5-(4-fluorophenyl)-3-hydroxypentyl]-5-
hydroxy-3-(hydroxyimino)-, ethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-18-9 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-5-(4-fluorophenyl)-3-hydroxypentyl]-5-
hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-19-0 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3R)-5-[3-fluoro-5-(trifluoromethyl)phenyl]-

3-hydroxypentyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-20-3 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-5-(3-fluorophenyl)-3-hydroxy-4-methylpentyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-21-4 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-(2-methoxyphenyl)pentyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-22-5 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-(3-methoxyphenyl)pentyl]-, 1-methylethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-23-6 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxy-6-
(2-thienyl)hexyl]-, methyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-24-7 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-
[3-(trifluoromethyl)phenyl]pentyl]-, methyl ester, (1R,2R,5S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-25-8 CAPLUS
CN Cyclopentaneheptanoic acid,
5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-

(2-methylphenyl)pentyl]-, 2,3-dihydroxypropyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-26-9 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-(3-methylphenyl)pentyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-27-0 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-phenylpentyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-28-1 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3S)-6-(2-furanyl)-3-hydroxyhexyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-29-2 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-5-(3-furanyl)-3-hydroxypentyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-30-5 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3S)-6-(3-bromophenyl)-3-hydroxyhexyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-31-6 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-2-[(3S)-3-hydroxy-6-phenylhexyl]-3-(methoxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-32-7 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3S)-6-(2-fluorophenyl)-3-hydroxyhexyl]-5-hydroxy-3-(methoxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-33-8 CAPLUS
CN Cyclopentaneheptanoic acid,
2-[(3S)-6-(3,5-difluorophenyl)-3-hydroxyhexyl]-
5-hydroxy-3-(methoxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-34-9 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-5-(3,5-difluorophenyl)-3-hydroxypentyl]-3-(ethoxyimino)-5-hydroxy-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-35-0 CAPLUS
CN Cyclopentaneheptanoic acid, 3-[(1,1-dimethylethoxy)imino]-2-[(3R)-5-(3-fluorophenyl)-3-hydroxypentyl]-5-hydroxy-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-36-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3R)-3-hydroxy-4,4-dimethyl-1-nonenyl]-3-(hydroxyimino)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-37-2 CAPLUS
CN Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-(hydroxyimino)-15-methyl-, (5Z,9.alpha.,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-38-3 CAPLUS
CN Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-(hydroxyimino)-15-methyl-, (5Z,9.alpha.,13E,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-39-4 CAPLUS
CN Prost-13-en-1-oic acid, 9,15-dihydroxy-11-(hydroxyimino)-, (9.alpha.,13E)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-40-7 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-41-8 CAPLUS
CN Prost-13-en-11-one, 1,9,15-trihydroxy-, oxime, (9.alpha.,13E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-42-9 CAPLUS
CN Prosta-5,13,17-trien-1-oic acid, 9,15-dihydroxy-11-(hydroxyimino)-, (5Z,9.alpha.,13E,17E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-43-0 CAPLUS
CN 5-Heptenoic acid,
7-[(1R,2R,5S)-2-[(1E,3S)-5-(2-fluorophenyl)-3-hydroxy-1-pentenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-44-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E)-3-hydroxy-6-phenyl-1-hexenyl]cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-45-2 CAPLUS
CN Cyclopentanone,
4-hydroxy-2-[(1E)-3-hydroxy-5-phenyl-1-pentenyl]-3-[(2Z)-6-(1H-tetrazol-5-yl)-2-hexenyl]-, oxime, (2R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



RN 365401-52-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E)-5-(2-fluorophenyl)-3-hydroxy-3-methyl-1-pentenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-53-2 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E)-3-ethyl-3-hydroxy-6-phenyl-1-hexenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-54-3 CAPLUS

CN Acetic acid, [4-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-(3-hydroxy-3-methyl-5-phenylpentyl)cyclopentyl]butoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-56-5 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(1E)-5-(2-fluorophenyl)-3-methyl-3-(methylamino)-1-pentenyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-58-7 CAPLUS
CN Cyclopentaneheptanamide,
N,5-dihydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-5-[3-(trifluoromethyl)phenyl]pentyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365401-59-8 CAPLUS
CN 5-Heptenamide,
7-[(1R,2R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(1E)-3-hydroxy-

5-phenyl-1-pentenyl]cyclopentyl]-N-(methylsulfonyl)-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-60-1 CAPLUS
CN Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-(hydroxyimino)-, (5Z,9.alpha.,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 365401-62-3 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[(3R)-3-hydroxy-4-(phenylthio)butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=> d 3 ibib abs hitstr l11

L11 ANSWER 3 OF 3 USPATFULL
ACCESSION NUMBER: 2002:22458 USPATFULL
TITLE: Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
INVENTOR(S): DeLong, Mitchell Anthony, West Chester, OH, UNITED STATES
McIver, John McMillan, Cincinnati, OH, UNITED STATES
Youngquist, Robert Scott, Mason, OH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013294	A1	20020131
APPLICATION INFO.:	US 2001-774558	A1	20010131 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193845	20000331 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL CENTER - BOX 474, 5299 SPRING GROVE
AVENUE, CINCINNATI, OH, 45217
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 1847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating **hair** loss in mammals uses compositions containing 2-decarboxy-2-phosphinico **prostaglandin** derivatives. The compositions can be applied topically to the skin. The compositions can arrest **hair** loss, reverse **hair** loss, and promote **hair** growth. Compositions containing 2-decarboxy-2-phosphinico **prostaglandin** derivatives can also be used to lower intraocular pressure and treat bone disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **365241-18-5P 365241-19-6P 365241-20-9P**
365241-21-0P 365241-22-1P 365241-23-2P
365241-24-3P 365241-25-4P 365241-26-5P
365241-27-6P
(cosmetic and pharmaceutical compns. contg. 2-decarboxy-2-phosphinico prostaglandin derivs.)
RN 365241-18-5 USPATFULL
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-[(3-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-19-6 USPATFULL
CN Phosphinic acid, ethyl[6-[(1R,5S)-2-[(3R)-4-[(2-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-20-9 USPATFULL
CN Phosphinic acid,
[6-[(1R,5S)-2-[(3R)-4-(3-fluorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-21-0 USPATFULL
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxyoctyl]cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-22-1 USPATFULL
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxynonyl]cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-23-2 USPATFULL
CN Phosphinic acid,
[6-[(1R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-24-3 USPATFULL
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-[(2,4-difluorophenyl)amino]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-25-4 USPATFULL
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-2-[(3S)-3-hydroxyoctyl]-3-(methoxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-26-5 USPATFULL
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-(benzo[b]thien-3-ylthio)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-27-6 USPATFULL
CN Phosphinic acid, butyl[6-[(1R,5S)-2-[(3R)-5-(2-fluorophenyl)-3-hydroxy-4-pentynyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



```
=> d his

     (FILE 'HOME' ENTERED AT 09:40:59 ON 12 MAR 2002)

     FILE 'REGISTRY' ENTERED AT 09:41:04 ON 12 MAR 2002
L1               STRUCTURE UPLOADED
L2               QUE L1
L3             9 S L2
L4           183 S L2 FULL

     FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, EMBASE' ENTERED AT 09:41:46 ON
     12 MAR 2002
L5            55 S L4
L6            49 DUP REM L5 (6 DUPLICATES REMOVED)
L7        289547 S PROSTAGLANDIN
L8            44 S L6 AND L7
L9        169447 S HAIR
L10       494459 S COSMETIC OR PHARMACEUTIC OR PHARMACEUTICAL
L11            3 S L8 AND L9
L12            8 S L8 AND L10

=> d l12 ibib abs hitstr

L12  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         2001:747564  CAPLUS
DOCUMENT NUMBER:          135:293970
TITLE:                    Cosmetic and pharmaceutical
                          compositions and methods using 2-decarboxy-2-
                          phosphinico prostaglandin derivatives
INVENTOR(S):              Delong, Mitchell Anthony; Mciver, John Mcmillan;
                          Youngquist, Robert Scott
PATENT ASSIGNEE(S):       The Procter + Gamble Company, USA
SOURCE:                   PCT Int. Appl., 54 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2001074314      A2   20011011       WO 2001-US10369  20010330
         W:  AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI,
             FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
```

MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002013294 A1 20020131 US 2001-774558 20010131
PRIORITY APPLN. INFO.: US 2000-193845 P 20000331
OTHER SOURCE(S): MARPAT 135:293970

AB Compns. contg. 2-decarboxy-2-phosphinico **prostaglandin** derivs. is described for treating hair loss in mammals. The compns. can be applied topically to the skin to arrest hair loss, reverse hair loss, and promote hair growth. Compns. contg. 2-decarboxy-2-phosphinico **prostaglandin** derivs. can also be used to lower intraocular pressure and treat bone disorders. A compn. comprises a **prostaglandin** analog, an activity enhancer, such as a hair growth stimulant and a penetration enhancer, and a sufficient amt. of a component selected from the group consisting of emollients, propellants, solvents, humectants, thickeners, powders, fragrances, water, alcs., aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, polypropylene glycol-2 myristyl propionate, di-Me isosorbide, and combinations thereof. For example, a compn. for topical administration was prepd. comprising (by wt.) a **prostaglandin** (IC50 = 114 nM) 1.14%, ethanol 59.32%, propylene glycol 19.77%, and di-Me isosorbide 19.77%. Also, a shampoo was made contg. ammonium lauryl sulfate 11.5%, ammonium laureth sulfate 4%, cocamide MEA 2%, ethylene glycol distearate 2%, cetyl alc. 2%, stearyl alc. 1.2%, glycerin 1%, sodium chloride 0.1%, sucrose polyesters of cottonate fatty acid 3%, sucrose polyesters of behenate fatty acid 2%, lauryl di-Me amine oxide 1.5%, DMDM hydantoin 0.15%, **prostaglandin** (IC = 150 nM) 0.15%, phenoxyethanol 0.5%, fragrance 0.5%, and water up to 100%. A tablet formulation was also prepd. contg. a **prostaglandin** 5 mg, microcryst. cellulose 100 mg, sodium starch glycolate 30 mg, and magnesium stearate 3 mg per tablet. When administered orally once daily, the above compn. substantially increases bone vol. in a patient suffering from osteoporosis.

IT **365241-18-5P 365241-19-6P 365241-20-9P**
365241-21-0P 365241-22-1P 365241-23-2P
365241-24-3P 365241-25-4P 365241-26-5P
365241-27-6P
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**cosmetic** and **pharmaceutical** compns. contg. 2-decarboxy-2-phosphinico **prostaglandin** derivs.)

RN 365241-18-5 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-[(3-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-19-6 CAPLUS
CN Phosphinic acid, ethyl[6-[(1R,5S)-2-[(3R)-4-[(2-fluorophenyl)thio]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-20-9 CAPLUS
CN Phosphinic acid,
[6-[(1R,5S)-2-[(3R)-4-(3-fluorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-21-0 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxyoctyl]cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-22-1 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-3-(hydroxyimino)-2-[(3S)-3-hydroxynonyl]cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-23-2 CAPLUS
CN Phosphinic acid,
[6-[(1R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-24-3 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-[(2,4-difluorophenyl)amino]-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-25-4 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-5-hydroxy-2-[(3S)-3-hydroxyoctyl]-3-(methoxyimino)cyclopentyl]hexyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-26-5 CAPLUS
CN Phosphinic acid, [6-[(1R,5S)-2-[(3R)-4-(benzo[b]thien-3-ylthio)-3-hydroxybutyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 365241-27-6 CAPLUS
CN Phosphinic acid, butyl[6-[(1R,5S)-2-[(3R)-5-(2-fluorophenyl)-3-hydroxy-4-pentynyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




```
=> d his

     (FILE 'HOME' ENTERED AT 09:40:59 ON 12 MAR 2002)

     FILE 'REGISTRY' ENTERED AT 09:41:04 ON 12 MAR 2002
L1               STRUCTURE UPLOADED
L2               QUE L1
L3             9 S L2
L4           183 S L2 FULL

     FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, EMBASE' ENTERED AT 09:41:46 ON
     12 MAR 2002
L5            55 S L4
L6            49 DUP REM L5 (6 DUPLICATES REMOVED)
L7        289547 S PROSTAGLANDIN
L8            44 S L6 AND L7
L9        169447 S HAIR
L10       494459 S COSMETIC OR PHARMACEUTIC OR PHARMACEUTICAL
L11            3 S L8 AND L9
L12            8 S L8 AND L10

=> s l12 not l11
L13            5 L12 NOT L11

=> d ibib abs hitstr

L13  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         1999:640832  CAPLUS
DOCUMENT NUMBER:          131:257381
TITLE:                    Preparation of C11-oximido prostaglandins useful as
FP
                          agonists
INVENTOR(S):              Delong, Mitchell Anthony; Amburgey, Jack Snyder, Jr.;
                          Wos, John August; De, Biswanath; Soper, David Lindsey
PATENT ASSIGNEE(S):       The Procter & Gamble Company, USA
SOURCE:                   PCT Int. Appl., 54 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 9950242         A1   19991007       WO 1999-IB480    19990322
         W:  AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
```

CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9932702	A1	19991018	AU 1999-32702		19990322
EP 1066254	A1	20010110	EP 1999-942611		19990322
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, MC, IE					
BR 9909268	A	20010904	BR 1999-9268		19990322
NO 2000004903	A	20001129	NO 2000-4903		20000929

PRIORITY APPLN. INFO.: US 1998-80216 P 19980331
WO 1999-IB480 W 19990322

OTHER SOURCE(S): MARPAT 131:257381

GI



I



II

AB Prostaglandins I (R1 = CO2H, C(O)NHOH, CO2R7, CH2OH, S(O)2R7, C(O)NHR7, C(O)NHS(O)2R7, or tetrazole where R7 = alkyl, heteroalkyl, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring; W = O, NH, S, S(O), S(O)2 or (CH2)m and m = 0-3; R2 = H;

R3 = H or lower alkyl, or R2R3 = bond; R4 = H, alkyl, heteroalkyl, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring; R5 = independently selected from H, CH3 and C2H5; X = NHR8 or OR8 where each R8 is independently selected from H, acyl, alkyl, heteroalkyl, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring; each R6 is independently selected from H, CH3, C2H5, OR8, NHR8; Y = O, NHR8, S, S(O), S(O)2 provided no carbon has more than one heteroatom attached; Z = H, Me, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring, bicyclic carbocyclic aliph. or heterocyclic aliph. ring, bicyclic arom. or heteroarom. ring provided that when Y = S,

S(O), or S(O)2 and Z = H, q is at least 1; a and b are independently a single bond, cis double bond or trans double bond; p = integer from 1 to 5, q = integer from 0 to 5, and p + q = 1 to 5) and any optical isomer, diastereomer, enantiomer of I or a pharmaceutically acceptable salt or biohydrolyzable amide, ester or imide were prepd. Oximido prostaglandins I are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Thus the 13,14-dihydro-16-phenylthio-16-tetranor PGD1.alpha. II (R = NOH; R9 = OH; R10 = H) was prepd. from Me 7-[3-(R)-hydroxy-5-oxo-1-cyclopenten-1-yl]heptanoate via the intermediate II (R = O; R9 = OAc; R10 = Me). The dosage range of the compd. for systemic administration is most preferably from about 1 to about 50.mu.g/kg body wt. per day and plasma levels for systemic administration are expected to be most preferably from 0.1 to 10 ng/mL.

IT **245127-04-2P 245127-13-3P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of C11-oximido prostaglandins useful as FP agonists)

RN 245127-04-2 CAPLUS
CN Cyclopentaneheptanoic acid, 5-hydroxy-3-(hydroxyimino)-2-[3-hydroxy-4-(phenylthio)butyl]-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 245127-13-3 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,5S)-2-[(3R)-5-(2-fluorophenoxy)-3-hydroxypentyl]-5-hydroxy-3-(hydroxyimino)cyclopentyl]-, methyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 2 ibib abs hitstr

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:640831 CAPLUS
DOCUMENT NUMBER: 131:271764
TITLE: Preparation of C11-oximido prostaglandins to treat bone disorders and glaucoma
INVENTOR(S): Delong, Mitchell Anthony; Amburgey, Jack Snyder, Jr.; Wos, John August; De, Biswanath; Soper, David Lindsey
PATENT ASSIGNEE(S): Procter & Gamble Co., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950241	A1	19991007	WO 1999-IB478	19990322
W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932701	A1	19991018	AU 1999-32701	19990322
BR 9909267	A	20001121	BR 1999-9267	19990322
EP 1082299	A1	20010314	EP 1999-942610	19990322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NO 2000004904	A	20001129	NO 2000-4904	20000929

PRIORITY APPLN. INFO.: US 1998-80075 P 19980331
WO 1999-IB478 W 19990322
OTHER SOURCE(S): MARPAT 131:271764
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Prostaglandins I (R1 = CO2H, C(O)NHOH, CO2R7, CH2OH, S(O)2R7, C(O)NHR7, C(O)NHS(O)2R7, or tetrazole where R7 = alkyl, heteroalkyl, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring; W = O, NH, S, S(O), S(O)2 or (CH2)m and m = 0-3; R2 = H; R3 = H or lower alkyl, or R2R3 = bond; R4 = H, alkyl, heteroalkyl, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring provided when each R5 and R6 = H, R4 = other than Me; R5 = independently selected from H, CH3 and C2H5; X = NHR8 or OR8 where each R8 is independently selected from H, acyl, alkyl, heteroalkyl, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring; each R6 is independently selected from H, CH3,

C2H5, OR8, NHR8; Z = H, Me, monocyclic carbocyclic aliph. or heterocyclic aliph. ring, monocyclic arom. or heteroarom. ring, bicyclic carbocyclic aliph. or heterocyclic aliph. ring, bicyclic arom. or heteroarom. ring; a and b are independently a single bond, cis double bond or trans double bond; p = integer from 0 to 6) and any optical isomer, diastereomer, enantiomer of I or a pharmaceutically acceptable salt or biohydrolyzable amide, ester or imide were prepd. Oximido prostaglandins I are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Thus the 13,14-dihydro-17-(2-fluorophenyl)-17-trinor PGD1.alpha. II was prepd. from III via the intermediate IV. The dosage range of the compd. for systemic administration is most preferably from about 1 to about 50 .mu.g/kg body wt. per day and plasma levels for systemic administration are expected to be most preferably from 0.1 to 10 ng/mL.

IT **245343-62-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of C11-oximido prostaglandins to treat bone disorders and glaucoma)

RN 245343-62-8 CAPLUS
CN Cyclopentaneheptanoic acid, 2-[(3R)-5-(2-fluorophenyl)-3-hydroxypentyl]-5-hydroxy-3-(hydroxyimino)-, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 3 ibib abs hitstr

L13 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER:	79:49944 USPATFULL
TITLE:	16,16-Spirocycloalkyl **prostaglandin** derivatives
INVENTOR(S):	Schaub, Robert E., Upper Saddle River, NJ, United States Weiss, Martin J., Oradell, NJ, United States
PATENT ASSIGNEE(S):	American Cyanamid Company, Stamford, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4178461		19791211	
APPLICATION INFO.:	US 1977-778302		19770316	(5)

RELATED APPLN. INFO.: Division of Ser. No. US 1975-592494, filed on 2 Jul 1975, now patented, Pat. No. US 4028396
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 4001
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This disclosure describes novel 15-hydroxy-16,16-spirocycloalkyl prostanoic acids and derivatives and congeners thereof which are useful as bronchodilators and gastric acid secretion inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **62408-09-7P 62408-11-1P**
(prepn. of)
RN 62408-09-7 USPATFULL
CN 5-Heptenoic acid, 7-[2-[3-(1-butylcyclobutyl)-3-hydroxy-1-propenyl]-3-hydroxy-5-(hydroxyimino)cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.



RN 62408-11-1 USPATFULL
CN 5-Heptenoic acid, 7-[2-[3-(1-butylcyclobutyl)-3-hydroxy-1-propenyl]-3-hydroxy-5-(methoxyimino)cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.



=> d 4 ibib abs hitstr

L13 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER:	77:29868 USPATFULL
TITLE:	16,16-Spirocycloalkyl **prostaglandin** derivatives
INVENTOR(S):	Schaub, Robert Eugene, Upper Saddle River, NJ, United States Weiss, Martin Joseph, Oradell, NJ, United States
PATENT ASSIGNEE(S):	American Cyanamid Company, Stamford, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4028396		19770607	
APPLICATION INFO.:	US 1975-592494		19750702	(5)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Gerstl, Robert
LEGAL REPRESENTATIVE:	Conroy, Jr., Edward A.
NUMBER OF CLAIMS:	31
EXEMPLARY CLAIM:	1
LINE COUNT:	4046

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure describes novel 15-hydroxy-16,16-spirocycloalkyl prostanoic acids and derivatives and congeners thereof which are useful as bronchodilators and gastric acid secretion inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **62408-09-7P 62408-11-1P**
(prepn. of)

RN 62408-09-7 USPATFULL

CN 5-Heptenoic acid, 7-[2-[3-(1-butylcyclobutyl)-3-hydroxy-1-propenyl]-3-hydroxy-5-(hydroxyimino)cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.



RN 62408-11-1 USPATFULL

CN 5-Heptenoic acid, 7-[2-[3-(1-butylcyclobutyl)-3-hydroxy-1-propenyl]-3-hydroxy-5-(methoxyimino)cyclopentyl]-, [1.alpha.(Z),2.beta.(1E,3R*),3.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as described by E or Z.



=> d 5 ibib abs hitstr

L13 ANSWER 5 OF 5 USPATFULL

ACCESSION NUMBER:	75:21151 USPATFULL
TITLE:	4,5,13-Prostatrienoic acid derivatives
INVENTOR(S):	Crabbe, Pierre, Grenoble, France Fried, John H., Palo Alto, CA, United States
PATENT ASSIGNEE(S):	Syntex (U.S.A.), Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3879438		19750422
APPLICATION INFO.:	US 1973-368983		19730611 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1973-338325, filed on 5 Mar 1973, now abandoned which is a continuation-in-part of Ser. No. US 1972-306414, filed on 14 Nov 1972, now abandoned which is a continuation-in-part of Ser. No. US 1971-204769, filed on 3 Dec 1971, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Gerstl, Robert
LEGAL REPRESENTATIVE:	Blaufarb, Gerard A., Simon, Leon, Walker, William B.
NUMBER OF CLAIMS:	86
EXEMPLARY CLAIM:	1
LINE COUNT:	4727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **prostaglandin** dehydro analogs of the PGE.sub.2 and PGF.sub.2.sub..alpha. series possessing diethylenic unsaturation in the carboxylic acid chain which may be further substituted at C-4, C-6 and/or C-15 by a methyl, ethyl or propyl group, the C-20 nor- or bisnor-derivatives, and certain C-20 alkyl derivatives thereof, processes for the production of such compounds and novel and useful intermediates obtained thereby. Also included are the pharmaceutically acceptable, non toxic esters and salts of the carboxylic acid function and the pharmaceutically acceptable, non toxic esters and/or ethers of the secondary hydroxyl groups. These compounds possess **prostaglandin** -like activities and thus are useful in the treatment of mammals, where prostaglandins are indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **50889-85-5P 50889-86-6P 50889-89-9P**
50889-90-2P
(prepn. of)

RN 50889-85-5 USPATFULL
CN Prosta-4,5,13-trien-1-oic acid, 11,15-dihydroxy-9-(hydroxyimino)-, methyl ester, (11.alpha.,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 50889-86-6 USPATFULL
CN Prosta-4,5,13-trien-1-oic acid, 11-hydroxy-9-(hydroxyimino)-15-oxo-, methyl ester, (11.alpha.,13E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 50889-89-9 USPATFULL
RN 50889-90-2 USPATFULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.81	210.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.10	-3.10

STN INTERNATIONAL LOGOFF AT 09:46:31 ON 12 MAR 2002